Clinical Trials Logo

Filter by:
NCT ID: NCT06110676 Recruiting - Psoriasis Clinical Trials

A Study to Evaluate the Efficacy and Safety of LZM012

Psoriasis
Start date: August 21, 2023
Phase: Phase 3
Study type: Interventional

This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients

NCT ID: NCT06110208 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

Start date: October 10, 2023
Phase: Early Phase 1
Study type: Interventional

This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population were patients with relapsed and refractory acute myeloid leukemia (r/r AML) .

NCT ID: NCT06109818 Recruiting - Clinical trials for Moderate to Severe Plaque Psoriasis

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Start date: January 4, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate ICP-488.Efficacy, safety, PK, and PD characteristics in Chinese adults with moderate to severe plaque psoriasis.

NCT ID: NCT06109805 Recruiting - Gastric Cancer Clinical Trials

Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis

Start date: October 20, 2023
Phase:
Study type: Observational

The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from gastric cancer patients using advanced mass spectrometry detection technology, in conjunction with both broad-spectrum and targeted metabolomics approaches. The goal is to construct a dedicated plasma metabolite database for gastric cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early gastric cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of gastric cancer.

NCT ID: NCT06109779 Recruiting - Clinical trials for Biliary Tract Cancer

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Start date: December 4, 2023
Phase: Phase 3
Study type: Interventional

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

NCT ID: NCT06109558 Recruiting - Clinical trials for Non Small Cell Lung Cancer

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

PROFILE
Start date: December 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy. The secondary endpoints of this study were to evaluated the efficacy HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy.

NCT ID: NCT06109480 Recruiting - Depressive Disorder Clinical Trials

Effect of HD-tDCS Assisted ECT for Depression Disorder

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

To investigate the intervention effect of high definition transcranial direct current stimulation (HD-tDCS) assisted Electroconvulsive Therapy (ECT) for depressive disorder.

NCT ID: NCT06109454 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery

Start date: March 21, 2024
Phase:
Study type: Observational

This study is a multicenter, prospective, and observational clinical study aimed at exploring whether the 3-year DFS in the Huaier group is not inferior to the control group receiving standard platinum dual-drug chemotherapy.

NCT ID: NCT06109337 Recruiting - ADHD Clinical Trials

Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder

Start date: December 4, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about The immune cell landscape of peripheral blood mononuclear cells in children with ADHD compared to typically developing controls. The main question it aims to answer are: 1.Testing the differences in immune cell subpopulations, protein expression and signaling pathways and cell subsets between two groups 2. Exploring the correlations between immune function in PBMC and resting-state brain functional networks in children with ADHD. Participants will be taken peripheral blood about 5 ml , cognitive assessment including Intelligence testing, Stroop color-word test and Trail making test, clinical interview and brain structural and functional MRI.

NCT ID: NCT06109311 Recruiting - Type 2 Diabetes Clinical Trials

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

ACHIEVE-5
Start date: November 10, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.